Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
25.06.25 | 19:43
14,550 Euro
-1,36 % -0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
14,55014,65022:57
14,45014,70022:00

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22:34Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025122TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial...
► Artikel lesen
DiTeva Pharmaceutical Industries Ltd: Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY (fremanezumab) für die Prävention chronischer und episodischer Migräne396Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2Fremanezumab demonstrierte...
► Artikel lesen
DiGoldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth28
MoTeva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic and Episodic Migraine362Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2Fremanezumab demonstrated sustained effectiveness...
► Artikel lesen
17.06.Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy12
17.06.Teva to collaborate with Fosun Pharma for TEV-562787
16.06.Teva Pharmaceutical: Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration375NORTHAMPTON, MA / ACCESS Newswire / June 16, 2025 / Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs. We engage...
► Artikel lesen
TEVA Aktie jetzt für 0€ handeln
16.06.Teva, Fosun Pharma Partner to Develop Immuno-Oncology Therapy14
16.06.Teva, Shanghai Fosun Partner To Develop TEV-56278383PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278...
► Artikel lesen
16.06.Teva and Fosun partner to develop TEV-56278 against cancers11
16.06.Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology129Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva...
► Artikel lesen
16.06.Teva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology375Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with...
► Artikel lesen
10.06.Teva Pharmaceutical: Teva Honored With Power of Partnership Award for Global Health Impact811NORTHAMPTON, MA / ACCESS Newswire / June 10, 2025 / Teva Pharmaceuticals has been recognized with the 2025 Power of Partnership Award by Americares, in collaboration with the Healthcare Distribution...
► Artikel lesen
10.06.Teva auf Goldman Sachs Konferenz: Strategische Neuausrichtung zur Biopharma45
06.06.Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?67
06.06.Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am39
06.06.Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space20
06.06.Teva Pharmaceutical: Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building742NORTHAMPTON, MA / ACCESS Newswire / June 6, 2025 / Teva Pharmaceutical:At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients...
► Artikel lesen
06.06.Goldman Sachs stuft Teva Pharm-Aktie mit "Kaufen" ein79
05.06.TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K, Current Report21
Weiter >>
292 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,2